IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v6y2015i1d10.1038_ncomms8708.html
   My bibliography  Save this article

A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus

Author

Listed:
  • Ying Wu

    (CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences
    Center for Influenza Research and Early-warning, Chinese Academy of Sciences)

  • MyungSam Cho

    (Biotechnology Research Institute, Celltrion, Inc.)

  • David Shore

    (Centers for Disease Control and Prevention)

  • Manki Song

    (International Vaccine Institute)

  • JungAh Choi

    (International Vaccine Institute)

  • Tao Jiang

    (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology)

  • Yong-Qiang Deng

    (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology)

  • Melissa Bourgeois

    (Centers for Disease Control and Prevention)

  • Lynn Almli

    (Centers for Disease Control and Prevention)

  • Hua Yang

    (Centers for Disease Control and Prevention)

  • Li-Mei Chen

    (Centers for Disease Control and Prevention)

  • Yi Shi

    (CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences
    Center for Influenza Research and Early-warning, Chinese Academy of Sciences
    Research Network of Immunity and Health, Beijing Institutes of Life Science, Chinese Academy of Sciences)

  • Jianxu Qi

    (CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences
    Center for Influenza Research and Early-warning, Chinese Academy of Sciences)

  • An Li

    (CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences
    College of Veterinary Medicine, Guangxi University)

  • Kye Sook Yi

    (Biotechnology Research Institute, Celltrion, Inc.)

  • MinSeok Chang

    (Biotechnology Research Institute, Celltrion, Inc.)

  • Jin Soo Bae

    (Biotechnology Research Institute, Celltrion, Inc.)

  • HyunJoo Lee

    (Biotechnology Research Institute, Celltrion, Inc.)

  • JiYoung Shin

    (Biotechnology Research Institute, Celltrion, Inc.)

  • James Stevens

    (Centers for Disease Control and Prevention)

  • SeoungSuh Hong

    (Biotechnology Research Institute, Celltrion, Inc.)

  • Cheng-Feng Qin

    (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology)

  • George F. Gao

    (CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences
    Center for Influenza Research and Early-warning, Chinese Academy of Sciences
    Research Network of Immunity and Health, Beijing Institutes of Life Science, Chinese Academy of Sciences
    Office of Director-General, Chinese Center for Disease Control and Prevention (China CDC))

  • Shin Jae Chang

    (Biotechnology Research Institute, Celltrion, Inc.)

  • Ruben O. Donis

    (Centers for Disease Control and Prevention)

Abstract

Effective annual influenza vaccination requires frequent changes in vaccine composition due to both antigenic shift for different subtype hemagglutinins (HAs) and antigenic drift in a particular HA. Here we present a broadly neutralizing human monoclonal antibody with an unusual binding modality. The antibody, designated CT149, was isolated from convalescent patients infected with pandemic H1N1 in 2009. CT149 is found to neutralize all tested group 2 and some group 1 influenza A viruses by inhibiting low pH-induced, HA-mediated membrane fusion. It promotes killing of infected cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. X-ray crystallographic data reveal that CT149 binds primarily to the fusion domain in HA2, and the light chain is also largely involved in binding. The epitope recognized by this antibody comprises amino-acid residues from two adjacent protomers of HA. This binding characteristic of CT149 will provide more information to support the design of more potent influenza vaccines.

Suggested Citation

  • Ying Wu & MyungSam Cho & David Shore & Manki Song & JungAh Choi & Tao Jiang & Yong-Qiang Deng & Melissa Bourgeois & Lynn Almli & Hua Yang & Li-Mei Chen & Yi Shi & Jianxu Qi & An Li & Kye Sook Yi & Min, 2015. "A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus," Nature Communications, Nature, vol. 6(1), pages 1-11, November.
    • Handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8708
    DOI: 10.1038/ncomms8708
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms8708
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms8708?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8708. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.